These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

430 related articles for article (PubMed ID: 28595287)

  • 1. Conversion to Parkinson Disease in the PARS Hyposmic and Dopamine Transporter-Deficit Prodromal Cohort.
    Jennings D; Siderowf A; Stern M; Seibyl J; Eberly S; Oakes D; Marek K;
    JAMA Neurol; 2017 Aug; 74(8):933-940. PubMed ID: 28595287
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Imaging prodromal Parkinson disease: the Parkinson Associated Risk Syndrome Study.
    Jennings D; Siderowf A; Stern M; Seibyl J; Eberly S; Oakes D; Marek K;
    Neurology; 2014 Nov; 83(19):1739-46. PubMed ID: 25298306
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical and Imaging Progression in the PARS Cohort: Long-Term Follow-up.
    Siderowf A; Jennings D; Stern M; Seibyl J; Eberly S; Oakes D; Marek K;
    Mov Disord; 2020 Sep; 35(9):1550-1557. PubMed ID: 32657461
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prospective clinical and DaT-SPECT imaging in premotor
    Sierra M; Martínez-Rodríguez I; Sánchez-Juan P; González-Aramburu I; Jiménez-Alonso M; Sánchez-Rodríguez A; Berciano J; Banzo I; Infante J
    Neurology; 2017 Aug; 89(5):439-444. PubMed ID: 28679601
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Olfactory testing combined with dopamine transporter imaging as a method to detect prodromal Parkinson's disease.
    Ponsen MM; Stoffers D; Wolters ECh; Booij J; Berendse HW
    J Neurol Neurosurg Psychiatry; 2010 Apr; 81(4):396-9. PubMed ID: 19965851
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serial olfactory testing for the diagnosis of prodromal Parkinson's disease in the PARS study.
    Vaswani PA; Morley JF; Jennings D; Siderowf A; Marek K;
    Parkinsonism Relat Disord; 2022 Nov; 104():15-20. PubMed ID: 36194902
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Longitudinal change in dopamine transporter availability in idiopathic REM sleep behavior disorder.
    Shin JH; Lee JY; Kim YK; Shin SA; Kim H; Nam H; Jeon B
    Neurology; 2020 Dec; 95(23):e3081-e3092. PubMed ID: 32989104
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical and dopamine transporter imaging characteristics of non-manifest LRRK2 and GBA mutation carriers in the Parkinson's Progression Markers Initiative (PPMI): a cross-sectional study.
    Simuni T; Uribe L; Cho HR; Caspell-Garcia C; Coffey CS; Siderowf A; Trojanowski JQ; Shaw LM; Seibyl J; Singleton A; Toga AW; Galasko D; Foroud T; Tosun D; Poston K; Weintraub D; Mollenhauer B; Tanner CM; Kieburtz K; Chahine LM; Reimer A; Hutten SJ; Bressman S; Marek K;
    Lancet Neurol; 2020 Jan; 19(1):71-80. PubMed ID: 31678032
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Motor and non-motor correlates of olfactory dysfunction in Parkinson's disease.
    Berendse HW; Roos DS; Raijmakers P; Doty RL
    J Neurol Sci; 2011 Nov; 310(1-2):21-4. PubMed ID: 21705022
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of RNA Blood Biomarkers in Individuals at Risk of Parkinson's Disease.
    Santiago JA; Potashkin JA
    J Parkinsons Dis; 2017; 7(4):653-660. PubMed ID: 28922168
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cognition and the course of prodromal Parkinson's disease.
    Weintraub D; Chahine LM; Hawkins KA; Siderowf A; Eberly S; Oakes D; Seibyl J; Stern MB; Marek K; Jennings D;
    Mov Disord; 2017 Nov; 32(11):1640-1645. PubMed ID: 29063713
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Is normosmic Parkinson disease a unique clinical phenotype?
    Lee DH; Oh JS; Ham JH; Lee JJ; Lee I; Lee PH; Kim JS; Sohn YH
    Neurology; 2015 Oct; 85(15):1270-5. PubMed ID: 26354986
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diagnosing premotor Parkinson's disease using a two-step approach combining olfactory testing and DAT SPECT imaging.
    Berendse HW; Ponsen MM
    Parkinsonism Relat Disord; 2009 Dec; 15 Suppl 3():S26-30. PubMed ID: 20083001
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hyposmia as a marker of (non-)motor disease severity in Parkinson's disease.
    Roos DS; Twisk JWR; Raijmakers PGHM; Doty RL; Berendse HW
    J Neural Transm (Vienna); 2019 Nov; 126(11):1471-1478. PubMed ID: 31515655
    [TBL] [Abstract][Full Text] [Related]  

  • 15. FDG PET, dopamine transporter SPECT, and olfaction: Combining biomarkers in REM sleep behavior disorder.
    Meles SK; Vadasz D; Renken RJ; Sittig-Wiegand E; Mayer G; Depboylu C; Reetz K; Overeem S; Pijpers A; Reesink FE; van Laar T; Heinen L; Teune LK; Höffken H; Luster M; Kesper K; Adriaanse SM; Booij J; Leenders KL; Oertel WH
    Mov Disord; 2017 Oct; 32(10):1482-1486. PubMed ID: 28734065
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combined DaT imaging and olfactory testing for differentiating parkinsonian disorders.
    Borghammer P; Knudsen K; Østergaard K; Danielsen EH; Pavese N; Arveschoug A; Bluhme H; Bode M; Morsing A
    Int J Clin Pract; 2014 Nov; 68(11):1345-51. PubMed ID: 24754902
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Selective hyposmia in Parkinson disease: association with hippocampal dopamine activity.
    Bohnen NI; Gedela S; Herath P; Constantine GM; Moore RY
    Neurosci Lett; 2008 Dec; 447(1):12-6. PubMed ID: 18838108
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Olfaction and imaging biomarkers in premotor LRRK2 G2019S-associated Parkinson disease.
    Sierra M; Sánchez-Juan P; Martínez-Rodríguez MI; González-Aramburu I; García-Gorostiaga I; Quirce MR; Palacio E; Carril JM; Berciano J; Combarros O; Infante J
    Neurology; 2013 Feb; 80(7):621-6. PubMed ID: 23325906
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dopamine reuptake transporter-single-photon emission computed tomography and transcranial sonography as imaging markers of prediagnostic Parkinson's disease.
    Noyce AJ; Dickson J; Rees RN; Bestwick JP; Isaias IU; Politis M; Giovannoni G; Warner TT; Lees AJ; Schrag A
    Mov Disord; 2018 Mar; 33(3):478-482. PubMed ID: 29380907
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Striatal Dopamine Transporter Modulation After Rotigotine: Results From a Pilot Single-Photon Emission Computed Tomography Study in a Group of Early Stage Parkinson Disease Patients.
    Rossi C; Genovesi D; Marzullo P; Giorgetti A; Filidei E; Corsini GU; Bonuccelli U; Ceravolo R
    Clin Neuropharmacol; 2017; 40(1):34-36. PubMed ID: 27941527
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.